Developing immunotherapeutic strategies for the control of Epstein-Barr virus-associated malignancies.
Denis J. Moss(The University of Queensland), Scott R. Burrows(Australian National University), Suzanne Elliott(The University of Melbourne), Martina A. Sherritt(The University of Queensland), Rajiv Khanna(QIMR Berghofer Medical Research Institute)
PubMed
August 1, 1999
Cited by 16
Related Papers
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
|The Journal of Experimental Medicine|1992|391
Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
|Proceedings of the National Academy of Sciences|1999|332
A Structural Basis for the Selection of Dominant αβ T Cell Receptors in Antiviral Immunity
|Immunity|2003|323
Estimating the global burden of Epstein–Barr virus-related cancers
|Journal of Cancer Research and Clinical Oncology|2021|313